Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of “Moderate Buy” by Analysts

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been given an average recommendation of “Moderate Buy” by the five research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $7.25.

RGLS has been the topic of several analyst reports. Canaccord Genuity Group reduced their price target on shares of Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 19th. Leerink Partnrs reissued an “outperform” rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. StockNews.com began coverage on shares of Regulus Therapeutics in a research report on Tuesday, April 16th. They issued a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Regulus Therapeutics in a research report on Monday. Finally, Wells Fargo & Company lifted their target price on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a report on Wednesday, March 13th.

Institutional Trading of Regulus Therapeutics

Several hedge funds have recently modified their holdings of the stock. Vivo Capital LLC acquired a new stake in Regulus Therapeutics in the 1st quarter valued at about $14,400,000. FMR LLC raised its holdings in Regulus Therapeutics by 32.4% in the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after acquiring an additional 716,000 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Regulus Therapeutics by 16.5% in the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 38,529 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Stock Performance

Shares of Regulus Therapeutics stock opened at $2.43 on Tuesday. The business’s 50 day moving average price is $2.32 and its 200 day moving average price is $1.69. The company has a market cap of $159.08 million, a price-to-earnings ratio of -1.53 and a beta of 1.59. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). On average, analysts predict that Regulus Therapeutics will post -0.52 EPS for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.